ACA
ENGN icon

Acorn Capital Advisors’s enGene Therapeutics ENGN Stock Holding History

Acorn Capital Advisors’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.2M Buy
+1,271,257
New +$5.18M 0.6% 17

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Acorn Capital Advisors's ENGN Position: Q2 2026 in Review

Acorn Capital Advisors opened a new position in enGene Therapeutics (ENGN) in Q2 2026: 1,271,257 shares worth $2.2M. The stake represents 0.6% of the portfolio and ranks #17 among its holdings.

60 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

  • Acorn Capital Advisors held 1,271,257 shares of enGene Therapeutics worth $2.2M as of Q2 2026.
  • enGene Therapeutics was a new Acorn Capital Advisors position in Q2 2026.
  • enGene Therapeutics made up 0.6% of Acorn Capital Advisors's portfolio in Q2 2026, its #17 holding.
  • 60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on Acorn Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.